Bio-Techne And Regulus Therapeutics Announced Continued Technical And Clinical Collaboration Following Regulus' Topline Results From The Second Cohort Of Phase 1B Multiple Ascending Study Of RGLS8429 For Autosomal Dominant Polycystic Kidney Disease

5/22/24 7:11:41 AM ET

$RGLS

$TECH

Biotechnology: Pharmaceutical Preparations

Health Care

Biotechnology: Biological Products (No Diagnostic Substances)

Health Care

Get the next $RGLS alert in real time by email

Bio-Techne And Regulus Therapeutics Announced Continued Technical And Clinical Collaboration Following Regulus' Topline Results From The Second Cohort Of Phase 1B Multiple Ascending Study Of RGLS8429 For Autosomal Dominant Polycystic Kidney Disease

Get the next $RGLS alert in real time by email

Chat with this insight

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$RGLS
$TECH

Company	Date	Price Target	Rating	Analyst
Regulus Therapeutics Inc. $RGLS	8/2/2024	$7.00	Outperform	Oppenheimer
Bio-Techne Corp $TECH	5/22/2024	$85.00	Buy → Neutral	Citigroup
Regulus Therapeutics Inc. $RGLS	3/18/2024	$6.00	Outperform	Leerink Partners
Bio-Techne Corp $TECH	2/8/2024	$80.00	Sector Outperform	Scotiabank
Bio-Techne Corp $TECH	2/2/2024	$65.00	Buy → Hold	Stifel
Bio-Techne Corp $TECH	12/7/2023	$80.00	Buy	UBS
Bio-Techne Corp $TECH	8/28/2023		Outperform	William Blair
Bio-Techne Corp $TECH	1/10/2023	$90.00	Underweight → Equal Weight	Wells Fargo

More analyst ratings

$RGLS
$TECH
Press Releases

Fastest customizable press release news feed in the world

Regulus Therapeutics Reports Third Quarter 2024 Financial Results and Recent Updates
Completed enrollment in the fourth cohort of the Phase 1b multiple-ascending dose (MAD) clinical trial of RGLS8429 for the treatment of autosomal dominant polycystic kidney disease (ADPKD) Presented a poster highlighting data from the ongoing MAD study of RGLS8429 in ADPKD at American Society of Nephrology (ASN) Kidney Week On track for an End-of-Phase 1 meeting by year-end Ended third quarter 2024 with cash, cash equivalents, and investments of $87.3 million; Cash runway into H1 2026 SAN DIEGO, Nov. 7, 2024 /PRNewswire/ -- Regulus Therapeutics Inc. (NASDAQ:RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs (the "Company"
11/7/24 4:05:00 PM ET
$RGLS
Biotechnology: Pharmaceutical Preparations
Health Care
ScaleReady Announces multiple G-Rex® Grants have been awarded to leading investigators at the Baylor College of Medicine's Center for Cell and Gene Therapy
ST. PAUL, Minn., Nov. 7, 2024 /PRNewswire/ -- ScaleReady, in collaboration with Wilson Wolf Manufacturing and Bio-Techne Corporation and CellReady, has awarded G-Rex Grants totaling $475,000 to three leading investigators at the Baylor College of Medicine's (BCM) Center for Cell and Gene Therapy Institute (CAGT). Dr. Ann Leen, a Professor in the Department of Pediatrics at BCM's CAGT, received a $275,000 G-Rex Grant for process development and IND enabling studies related to tumor-associated neoantigen specific T cell therapies for the treatment of acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) in pre- and post-hematopoietic stem cell (HSC) transplant. Dr. Leen has been wit
11/7/24 7:00:00 AM ET
$TECH
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
BIO-TECHNE TO PRESENT AT THE SOCIETY FOR IMMUNOTHERAPY OF CANCER (SITC) 39TH ANNUAL MEETING
MINNEAPOLIS, Nov. 6, 2024 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ:TECH) today announced it will showcase its market-leading portfolio to advance cancer research from target discovery to personalized medicine and cell therapy development at the Society for Immunotherapy of Cancer (SITC) 39th Annual Meeting, taking place November 6-10, 2024, in Houston, Texas. Bio-Techne's spatial biology brands, Advanced Cell Diagnostics (ACD) and Lunaphore, are revolutionizing spatial biology research with their pioneering innovations that are advancing the development of tailored immunotherapies to improve patient outcomes. At booth #613, ACD will present its wide range of spatial multiomics products
11/6/24 7:00:00 AM ET
$TECH
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care

BIO-TECHNE RELEASES FIRST QUARTER FISCAL 2025 RESULTS
MINNEAPOLIS, Oct. 30, 2024 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ:TECH) today reported its financial results for the first quarter ended September 30, 2024. First Quarter FY2025 Highlights First quarter organic revenue increased by 4% (5% reported) to $289.5 million. GAAP earnings per share (EPS) was $0.21 versus $0.31 one year ago. Delivered adjusted EPS of $0.42 compared to $0.41 one year ago. Continued adoption and utilization across the Diagnostics & Spatial Biology ("DSS"), formerly Diagnostics & Genomics, portfolio led to 14% organic segment growth (14% reported). Continued uptake of our cell and gene therapy workflow solutions, including strong growth in our GMP reagent offeri
10/30/24 6:30:00 AM ET
$TECH
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
BIO-TECHNE DECLARES DIVIDEND
MINNEAPOLIS, Oct. 30, 2024 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ:TECH) announced that its Board of Directors has decided to pay a dividend of $0.08 per share for the quarter ended September 30, 2024. The quarterly dividend will be payable November 22, 2024, to all common shareholders of record on November 11, 2024. Future cash dividends will be considered by the Board of Directors on a quarterly basis. Bio-Techne Corporation (NASDAQ: TECH) is a global life sciences company providing innovative tools and bioactive reagents for the research and clinical diagnostic communities. Bio-Techne products assist scientific investigations into biological processes and the nature and progress o
10/30/24 6:30:00 AM ET
$TECH
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
BIO-TECHNE TO HOST CONFERENCE CALL ON OCTOBER 30, 2024, TO ANNOUNCE FIRST QUARTER FISCAL 2025 FINANCIAL RESULTS
MINNEAPOLIS, Oct. 10, 2024 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ:TECH) today announced that management will host a conference call and webcast on Wednesday, October 30, 2024, at 8:00 a.m. CDT to review its first quarter fiscal 2025 financial results. Access to the discussion may be obtained as follows: Time: 8:00 a.m. CDT Date: October 30, 2024 Dial-in: 1-877-407-9208 or 1-201-493-6784 (for international callers) Conference ID: 13749405 Webcast: https://investors.bio-techne.com/ir-calendar A recorded rebroadcast will be available for interested parties unable to participate in the live conference call by dialing 1-844-512-2921 or 1-412-317-6671 (for international callers) and refere
10/10/24 7:00:00 AM ET
$TECH
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care

$RGLS
$TECH
Leadership Updates

Live Leadership Updates

BIO-TECHNE APPOINTS DR. JUDITH KLIMOVSKY TO BOARD OF DIRECTORS
MINNEAPOLIS, April 30, 2024 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ:TECH) today announced the appointment of Dr. Judith Klimovsky to serve as an independent director on the Company's Board of Directors, April 24, 2024. Dr. Klimovsky will serve as a member of the Science and Technology Committee. Following the appointment, the board of Bio-Techne will be temporarily comprised of eleven directors, ten of whom are independent. Dr. Klimovsky is currently the Executive Vice President and Chief Development Officer at Genmab, an international biotechnology company specialized in the creation and development of antibody therapeutics. Before joining Genmab in 2017, Dr. Klimovsky held various s
4/30/24 7:00:00 AM ET
$TECH
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
BIO-TECHNE ANNOUNCES APPOINTMENT OF MATTHEW F. McMANUS AS PRESIDENT, DIAGNOSTICS AND GENOMICS SEGMENT
MINNEAPOLIS, Jan. 5, 2024 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ:TECH) today announced Matthew F. McManus has been appointed President, Diagnostics and Genomics Segment, effective January 8, 2024. Dr. McManus succeeds Kim Kelderman, who will become Bio-Techne's Chief Executive Officer effective February 1, 2024. Dr. McManus has over two decades of experience as a senior life sciences leader, most recently serving as Executive Vice President and Chief Operating Officer for Azenta, where he was responsible for Life Sciences Products, Services, and all commercial operations of the business. Previously, Dr. McManus was Senior Vice President and General Manager of Bio-Techne's Molecular D
1/5/24 7:00:00 AM ET
$TECH
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
Regulus Therapeutics Reports Second Quarter 2023 Financial Results and Recent Updates
First patient dosed in second cohort of patients with Autosomal Dominant Polycystic Kidney Disease (ADPKD) in Phase 1b Multiple-Ascending Dose (MAD) study of RGLS8429 R&D Day to discuss our ADPKD program to be held Wednesday, September 6th Strengthened leadership through appointments of Preston S. Klassen, M.D. as President and Head of Research & Development and Curtis A. Monnig, Ph.D. as Vice President of CMC SAN DIEGO, Aug. 8, 2023 /PRNewswire/ -- Regulus Therapeutics Inc. (NASDAQ:RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs (the "Company" or "Regulus"), today reported financial results and provided a corporate upd
8/8/23 4:05:00 PM ET
$RGLS
Biotechnology: Pharmaceutical Preparations
Health Care

Bio-Techne And Regulus Therapeutics Announced Continued Technical And Clinical Collaboration Following Regulus' Topline Results From The Second Cohort Of Phase 1B Multiple Ascending Study Of RGLS8429 For Autosomal Dominant Polycystic Kidney Disease

Chat with this insight

Recent Analyst Ratings for $RGLS$TECH

$RGLS$TECH Insider Purchases

Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

Director Collier Kathryn J bought $7,280 worth of shares (4,000 units at $1.82), increasing direct ownership by 146% to 6,740 units (SEC Form 4)

$RGLS$TECH Large Ownership Changes

This live feed shows all institutional transactions in real time.

Amendment: SEC Form SC 13G/A filed by Regulus Therapeutics Inc.

SEC Form SC 13G filed by Regulus Therapeutics Inc.

SEC Form SC 13G/A filed by Regulus Therapeutics Inc. (Amendment)

$RGLS$TECH Press Releases

Fastest customizable press release news feed in the world

Regulus Therapeutics Reports Third Quarter 2024 Financial Results and Recent Updates

ScaleReady Announces multiple G-Rex® Grants have been awarded to leading investigators at the Baylor College of Medicine's Center for Cell and Gene Therapy

BIO-TECHNE TO PRESENT AT THE SOCIETY FOR IMMUNOTHERAPY OF CANCER (SITC) 39TH ANNUAL MEETING

$RGLS$TECH Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

Oppenheimer initiated coverage on Regulus Therapeutics with a new price target

Bio-Techne downgraded by Citigroup with a new price target

Leerink Partners initiated coverage on Regulus Therapeutics with a new price target

$RGLS$TECH Financials

Live finance-specific insights

$RGLS$TECH SEC Filings

BIO-TECHNE RELEASES FIRST QUARTER FISCAL 2025 RESULTS

BIO-TECHNE DECLARES DIVIDEND

BIO-TECHNE TO HOST CONFERENCE CALL ON OCTOBER 30, 2024, TO ANNOUNCE FIRST QUARTER FISCAL 2025 FINANCIAL RESULTS

SEC Form 10-Q filed by Regulus Therapeutics Inc.

Regulus Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition

Bio-Techne Corp filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits

$RGLS$TECH Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

PRESIDENT, PROTEIN SCIENCES Geist William converted options into 9,912 shares and covered exercise/tax liability with 3,270 shares, increasing direct ownership by 150% to 11,081 units (SEC Form 4)

Chief Executive Officer Kelderman Kim covered exercise/tax liability with 2,430 shares, decreasing direct ownership by 6% to 39,004 units (SEC Form 4)

CFO Hippel James converted options into 13,159 shares and covered exercise/tax liability with 6,475 shares, increasing direct ownership by 7% to 106,610 units (SEC Form 4)

$RGLS$TECH Leadership Updates

Live Leadership Updates

BIO-TECHNE APPOINTS DR. JUDITH KLIMOVSKY TO BOARD OF DIRECTORS

BIO-TECHNE ANNOUNCES APPOINTMENT OF MATTHEW F. McMANUS AS PRESIDENT, DIAGNOSTICS AND GENOMICS SEGMENT

Regulus Therapeutics Reports Second Quarter 2023 Financial Results and Recent Updates

$RGLS$TECH Market Insights

Live Market Insights

HC Wainwright & Co. Reiterates Buy on Regulus Therapeutics, Maintains $10 Price Target

Canaccord Genuity Maintains Buy on Regulus Therapeutics, Raises Price Target to $28

Ball To Rally More Than 23%? Here Are 10 Top Analyst Forecasts For Tuesday

Recent Analyst Ratings for
$RGLS
$TECH

$RGLS
$TECH
Insider Purchases

$RGLS
$TECH
Large Ownership Changes

$RGLS
$TECH
Press Releases

$RGLS
$TECH
Analyst Ratings

$RGLS
$TECH
Financials

$RGLS
$TECH
SEC Filings

$RGLS
$TECH
Insider Trading

$RGLS
$TECH
Leadership Updates

$RGLS
$TECH
Market Insights